Afeyan Noubar's Form 4 filing
Generate Biomedicines, Inc. (GENB) · filed Mar 2, 2026
- Accession no.
- 0001193125-26-085888
- Filed
- Mar 2, 2026, 5:52 PM ET
- Trade date
- Feb 26-Mar 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 11 derivative transactions. Open-market purchases total $75.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Afeyan NoubarCIK 0001222012 | Director, 10% Owner |
| Flagship Pioneering, LLCCIK 0001400240 | 10% Owner |
| Flagship Pioneering Fund VI General Partner LLCCIK 0001724957 | 10% Owner |
| Nutritional Health LTP Fund General Partner LLCCIK 0001780951 | 10% Owner |
| Flagship Pioneering Fund VII General Partner LLCCIK 0001805917 | 10% Owner |
| Flagship Pioneering Special Opportunities Fund II General Partner LLCCIK 0001826217 | 10% Owner |
| FPN General Partner LLCCIK 0001860059 | 10% Owner |
| Flagship VentureLabs VI Manager LLCCIK 0001860060 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Common Stock | CConversionAcquired | +12,723,940 | –F1 | – | 12,723,940 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionAcquired | +13,702,224 | –F1 | – | 13,702,224 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionAcquired | +987,491 | –F1 | – | 987,491 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionAcquired | +2,777,752 | –F1 | – | 2,777,752 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionAcquired | +2,777,752 | –F1 | – | 2,777,752 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | PPurchaseAcquired | +1,562,500 | $16.00 | +$25,000,000 | 15,264,724 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | PPurchaseAcquired | +1,562,500 | $16.00 | +$25,000,000 | 4,340,252 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | PPurchaseAcquired | +1,562,500 | $16.00 | +$25,000,000 | 1,562,500 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Common Stock | AGrant or awardAcquired | +29,561 | $0.00 | $0 | 29,561 | Direct | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −12,168,390 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −11,202,248 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −987,491 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −555,550 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −833,325 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −1,944,427 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −1,388,876 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −1,666,651 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −833,325 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Mar 2, 2026 | Common Stock | CConversionDisposed | −1,388,876 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Referenced by the price of 5 transactions in Table I.
Remarks
Form 2 of 2: This is the second of two Forms 4 being filed relating to the same event. The Form 4 is being split into two filings because there are more than 10 Reporting Persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 Reporting Persons. Each Form 4 is filed by Designated Filer Noubar Afeyan.